News Generate's IPO gets over the line, raising $400m AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.
News COPD patients will get access to Dupixent via NHS Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.
News China clears GSK's Nucala for COPD GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.
News GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
News GSK strikes again, adding COPD candidate in $745m deal In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.
News AZ's bid for Fasenra approval in COPD falls short AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.